Ensuring equitable access to medicines is a cornerstone of the commitments many pharmaceutical companies make to their customers, patients, and stakeholders – but, recently, there has been
The pharmaceutical industry is undergoing a profound transformation, driven by the increasing complexity of drug development and the need for greater efficiency and cost-effectiveness.
Europeans are living longer than ever before – tangible proof of the phenomenal advancements in science and healthcare.1,2 However, it comes with a paradoxical rise in nervous sy
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
